Dr. Mikhail Blagosklonny has long held that Rapamycin extends life and reduces aging and is considered the most vocal scientist for advocating the anti-aging qualities of Rapamycin. In his article for Aging US, Dr. Blagosklonny rejected the assertion that Rapamycin could extend life and not reduce aging as self-contradictory. It is impossible to extend life without reducing aging since the extension of life involves reducing the purposeless development of cells. For Rapamycin therefore to extend life it must reduce aging. The anti-aging drug Rapamycin has discovered accidentally in the Easter islands and has been proven over the years to prolong life and contain properties that enhance the healing of cancer. The bone of contention among scientists, however, has been on the ability of the drug to slow down or stop aging altogether. At the fore front of the school of thought that it can reduce aging has been Dr. Mikhail Blagosklonny.
Aging is described as the increased probability of death occasioned by the advancement in age. As people grow older, they have higher chances of dying of natural causes. Most of such diseases involve organ failure and heart diseases. Aging is occasioned, in turn, by the cellular aging. Cellular aging is a process that depends heavily on mechanistic or mammalian target of rapamycin, denoted as MTOR. As individuals advance in age, the most potent danger for them is posed by hyper bodily functions. These are such eventualities as hypertension, high blood pressure, and hyper-aggression. To extend human life, the cellular aging process must be reduced to reduce the chances of hyper function as explained. It therefore follows Dr. Mikhail Blagosklonny holds, that rapamycin would have the right qualities to reduce aging of it can extend human life.
Dr. Mikhail Blagosklonny is a scientist, researcher and philanthropist who has committed a long part of his adult life in seeking ways to ensure that all members of society can receive treatment and access to medical care despite their socioeconomic standing. He has specialized more in the field of research, holding the position of editor-in-chief for the scientific journal Oncotarget, published by Impact Journals. Dr. Blagosklonny is particularly interested in research on cancer and aging and is more concerned with discerning the connection between cancer and aging. He has continually questioned the reason why cancer is more prevalent among people above a certain age limit. He sees this as pointing to direct relationship between cancer and aging and believes very strongly that finding the cure for cancer is deeply intertwined with the finding of an anti-ageing drug or therapy. It is, therefore, no surprise that he has put his weight behind rapamycin as a possible anti-aging disease since it has been proven t have the ability to extend life and reduce the effects of cancer drastically.